# Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

> **NCT04023669** · PHASE1 · COMPLETED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 21 (actual)

## Conditions studied

- Brain Tumor
- Brain Tumor, Recurrent
- Brain Tumor, Refractory
- Brain Tumor, Pediatric
- Medulloblastoma
- Medulloblastoma Recurrent
- Medulloblastoma, Non-WNT/Non-SHH
- Medulloblastoma, Non-WNT/Non-SHH, Group 3
- Medulloblastoma, Non-WNT/Non-SHH, Group 4
- Brain Cancer
- CNS Cancer
- CNS Tumor
- CNS Neoplasm

## Interventions

- **DRUG:** Prexasertib
- **DRUG:** Cyclophosphamide
- **DRUG:** Gemcitabine
- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** peg-filgrastim

## Key facts

- **NCT ID:** NCT04023669
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-08
- **Primary completion:** 2023-05-01
- **Final completion:** 2025-01-13
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04023669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04023669, "Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04023669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*